Newton Fund - Development of a rapid ParaDNA test kit for improved clinical management of patients with breast cancer and associated co-morbidities

牛顿基金 - 开发一种快速 ParaDNA 检测试剂盒，以改善乳腺癌及相关并发症患者的临床管理

• 批准号: 103993
• 金额: $ 23.82万
• 依托单位: LGC LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=103993
• 关键词: Newton; Fund; Development; rapid; ParaDNA

Non-communicable diseases (NCDs) including cancer and cardiovascular disease (CVD) are major causes of death globally. The South African Medical Research Council (SAMRC) has responded to the dire need for translatable research by supporting the development of a novel genetic testing platform focused on disease pathways that are shared by many NCDs. To link to the United Nations' Sustainable Development Goal of ensuring health and promoting well-being, LGC (UK) in collaboration with the SAMRC's spinout company, Gknowmix, and Stellenbosch University has developed a novel point of care (PoC) diagnostic testing system and screening tool to improve the clinical management of patients with breast cancer and its associated co-morbidities. This testing platform is made possible by using the LGC ParaDNA technology that enables detection of genetic changes that are important in the development of breast cancer. Genetic testing may be done by non-expert users and within 1 hour, compared to standard laboratory methods that takes 1 week from sample collection to result reporting. For the first time, PoC technology will be used to detect changes in the two main breast cancer susceptibility genes (BRCA1 and BRCA2), as well as changes in other genes shared by various NCDs. The patient reports generated using this technology helps to determine whether further testing is necessary in patients with treatment failure, medication side-effects or co-morbidities that are not explained by the initial assessment. Combining the unique ParaDNA PoC technology with the proprietary algorithms of Gknowmix, enables this system to be scaled in South Africa and globally, with significant benefit to patients with breast cancer and those at risk of developing CVD and other associated NCDs. The availability of genetic testing at the PoC enables better access to genetic testing and overall care, reduced costs and faster reporting for timely implementation of effective intervention strategies.

包括癌症和心血管疾病（CVD）在内的非通信疾病（NCD）是全球死亡的主要原因。南非医学研究委员会（SAMRC）通过支持开发一个针对许多NCD共享的疾病途径的新型基因测试平台的发展，对可译文研究的迫切需求做出了回应。为了与联合国的可持续发展目标联系起来，确保健康和促进福祉，LGC（英国）与SAMRC的纺纱公司，GknowMix和Stellenbosch University合作开发了一种新颖的护理点（POC）诊断测试系统，并筛选工具，以改善乳腺癌及其相关的co-Morbidity患者的临床管理。通过使用LGC Paradna技术，该测试平台成为可能，该技术可以检测到对乳腺癌发展很重要的遗传变化。与标准实验室方法相比，非专家用户可以在1小时内完成基因测试，该方法需要从样本收集到结果报告1周。 POC技术将首次用于检测两个主要的乳腺癌易感基因（BRCA1和BRCA2）的变化，以及各种NCD共享的其他基因的变化。使用该技术生成的患者报告有助于确定在治疗失败，药物副作用或合并症患者中是否需要进一步测试，而初步评估未解释。将独特的Paradna POC技术与GknowMix的专有算法相结合，使该系统能够在南非和全球范围内进行缩放，对乳腺癌患者以及有患有CVD和其他相关NCD的风险的患者有很大的好处。 POC的基因检测的可用性使得可以更好地获得基因检测和整体护理，降低成本和更快的报告，以及时实施有效的干预策略。